WCLC 2023 | A Phase II study of I-SABR in early or recurrent NSCLC

Joe Chang, MD, PhD, The University of Texas MD Anderson Cancer Centre, Houston, TX, outlines the study design of the Phase II trial (NCT03110978) of stereotactic ablative radiotherapy (SABR) combined with nivolumab in early stage or recurrent isolated non-small cell lung cancer (NSCLC). Despite SABR being the standard of care for local control, a significant number of patients with NSCLC experience secondary lung cancers or lymph node malignancies; consequently, current research aims to investigate the combination of immunotherapy and SABR (I-SABR) to reduce regional or distant recurrences. Dr Chang describes the goals of a randomised Phase II study in which I-SABR (multiple doses of nivolumab alongside SABR) is compared with SABR alone in patients with early stage or recurrent isolated NSCLC. This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.